

THE UNIVERSITY OF SYDNEY

Does Immediate Breast Reconstruction lead to a delay in Adjuvant Chemotherapy for Breast Cancer? A Meta-analysis and Systematic Review

Cook Patrick² Eslick Guy² Edirimanne Senarath¹²

¹Department of Surgery, Nepean Hospital, Sydney, NSW, Australia ²Nepean Clinical School, The University of Sydney, Sydney, NSW, Australia

Problem Statement

In a multidisciplinary approach to breast cancer, timely delivery of adjuvant chemotherapy is crucial. With an increasing frequency of immediate breast reconstructions (IBR) following mastectomy (MAS), concerns have arisen regarding its complication rates and effects on time to chemotherapy

Aim

This research aims analyse whether or not undergoing an immediate breast reconstruction following mastectomy for breast cancer leads to delays in time to adjuvant chemotherapy, with a meta analysis and

Methods

23 original studies were identified following PRISMA guidelines, using seven electronic databases, hand-searched reference lists, review articles, and conference abstracts. Eligibility criteria included women receiving adjuvant chemotherapy who underwent either mastectomy only or mastectomy and immediate breast reconstruction. The primary outcome was time to chemotherapy (TTC) after surgery and secondary outcome was complication rates. A Random-effects model was used in the analysis.

systematic review

Results

23 studies were included in analysis.

Patient numbers


Total number of patients was 7163 (IBR: 2891; MAS: 4272). 55% of IBR performed were autologous compared to 54% prosthetic IBR. TTC in IBR was 44.23 days [SD: 15.56] vs MAS: 39.85 days [SD: 15.25] (p>0.001).

Delays past 90 days and complications

Difference in mean number of patients delayed past 90 days was not significant in IBR: 10.7 vs 10.4 MAS (p=0.90). IBR patients were more likely to have complications compared to the MAS group (OR: 1.82, 95% CI: 1.03-3.20, p=0.04).

Delays in chemotherapy stratified based on reconstruction type

Median TTC in autologous IBR was 37.67 [SD: 21.46] and median TTC in prosthetic IBR was 35.26 [SD: 20.98]. Different reconstruction methods yielded different mean TTC. Transverse rectus abdominis flaps (TRAM) had a median time of 43.20 days [SD: 4.9], Prosthetic 35.26 days [SD: 4.90], Latissimus Dorsi (LD) flap was 31.65 days [SD: 13.4] and Deep inferior epigastric perforator artery (DIEP) flap was 27.10 [SD: 13.4].



mmediate Breast Mastectomy only Total Reconstruction

Time to Chemotherapy

	Mastectomy only	Immediate Breast Reconstruction	
Number	4272	2981	
Median time to chemotherapy (days)	39.85	44.3	
Standard deviation	15.29	15.56	
Figure 2: Results of meta analysis of comparing time to chemotherapy for mastectomy and IBR			

7163	4272	2891		IBR	Odds
nt numbers inc	cluded in meta	analysis	1		
rence	P-va	alue		MAS	
	p<0	.001		Complic ations	1.8
chemoth				Figure 4: C complicati	
	Pati	ents	De	layed	Pas
			Ma	stectomy	only
	nt numbers inc rence of days : Differe	nt numbers included in meta rence P-va ence of p<0 days : Difference in m chemotherapy b d IBR	nt numbers included in meta analysis rence P-value ence of p<0.001 days : Difference in median chemotherapy between d IBR	nt numbers included in meta analysis rence P-value ence of p<0.001 chays : Difference in median chemotherapy between d IBR Patients De	Image: Image

Complications

IBR VS MAS	Odds Ratio	Lower Limit	Upper limit	P-value
Complic ations	1.82	1.03	3.20	0.04

omparing likelihood of in IBR to MAS

st 90 Days

	DIEP	LD	All Prosthetic	All Autologous	TRAM
Mean time to chemotherapy (days)	27.10	31.65	35.26	37.67	43.20

	Mastectomy only	Immediate Breast Reconstruction
Total patient numbers delayed past 90 days	73	118

Standard deviation	20.98	21.46	4.90	13.40	7.50

Figure 5: Difference in median time to chemotherapy stratified on method of reconstruction

Mean number of patients delayed past 90 days	10.72	10.43
Difference	0.29	p=0.90

Figure 6: Difference in time to chemotherapy between Mastectomy only and Immediate Breast Reconstruction

Conclusion

We concluded that there is a statistically significant longer time to chemotherapy following IBR of 4.38 days, yet there no difference in delays past 90 days. Therefore, the longer TTC in IBR is unlikely to be of any clinical

Acknowledgements: Prof G.Eslick for his contribution to the data analysis and A/Prof Edirimanne for his guidance and editing

Acknowledgments

Contact: Patrick Cook is a penultimate year medical student at the University of Sydney He can be contacted via his email: patjamescook@gmail.com

cignificanco